ArticleDiscover oncology2026
Unveiling membrane transporter proteins-related genes for predicting the prognosis of hepatocellular carcinoma patients.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundPrior research has indicated that membrane transporter proteins may play a role in tumorigenesis, progression, and mechanisms of drug resistance in hepatocellular carcinoma (HCC) by affecting the transport of drugs, nutrients, and metabolites. Therefore, a comprehensive elucidation of the role of membrane transporter protein-related genes (MTPRGs) in the outcome of those suffering with HCC is essential.
methodsThe bulk RNA data/survival information/clinical records of HCC patients were retrieved from the UCSC Xena and the Gene Expression Omnibus databases. Through combining differential analysis, the protein-protein interaction construction, univariate COX regression analysis, and least absolute shrinkage and selection operator (LASSO), the membrane transporter protein-related prognostic genes were identified, and the prognostic model was subsequently formulated. The relation between risk score and immune infiltration, clinical features, and chemotherapy was further evaluated. The expression of prognostic genes was afterwards assessed by in vitro tests.
resultsThrough a comprehensive analysis, three membrane transporter protein-related prognostic genes (SLC1A5, SLC38A1, and GPD1L) for HCC patients were identified. Moreover, the prognostic model demonstrated robust predictive efficacy for predictions of individuals with HCC. Additionally, risk score had significant associations with immune infiltration, clinical features, and chemotherapy. Furthermore, SLC1A5, SLC38A1, and GPD1L were all highly expressed in the HCC samples.
conclusionOur research generated a risk model incorporating MTPRGs which shown strong predictive effectiveness for the prognosis of HCC patients, which will offer novel insights to guide subsequent therapy strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.